Company intelligence / Profile preview
Syngen Biotech
Taiwansyngenbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Syngen Biotech has commercialized multiple probiotic and fermentation-based nutraceuticals, including products scientifically proven to enhance gut health and metabolism (e.g., GUARDSPO BC198® with proven colonization and S38+BC198 with lipid reduction claims); also awarded for innovations in APIs and cordyceps cultivation
- Therapeutic areas
- ImmunologyEndocrinologyMetabolic DisordersGastroenterologyDermatologyOtherNeurologyWomen's Health
- Modalities
- ProbioticsSmall moleculeFermentation-derived biologicNutraceutical ingredients
- Industry
- Food & Nutrition
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Syngen Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syngen Biotech.